Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

HealthDay News — The prevalence of post-COVID-19 condition (PCC) was 8.4% among US adults in 2023, according to a research letter published online in JAMA Network Open.

Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Factors associated with higher odds of antiviral receipt include clinical influenza testing and ICU admission.

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

As long as a drug shortage is declared, compounding pharmacies are still eligible to produce their own versions of Zepbound/Mounjaro. HealthDay News — The US Food and Drug Administration re ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups. Black mothers are faced with a disproportionate number of barriers ...